Sanofi, Principia agree to develop multiple sclerosis drug candidate
Sanofi | November 09, 2017
Sanofi will develop Principia Biopharma Inc.'s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, another central nervous system (CNS) diseases. Under the license agreement signed this week.